Sernova (TSE:SVA) Announces Earnings Results

Sernova (TSE:SVA) announced its quarterly earnings data on Friday. The company reported C$0.01 EPS for the quarter, FiscalAI reports.

Sernova Trading Down 2.9%

Shares of SVA opened at C$0.17 on Friday. The firm has a market cap of C$57.24 million, a P/E ratio of -3.40 and a beta of -0.06. The company has a debt-to-equity ratio of -68.92, a current ratio of 0.02 and a quick ratio of 18.11. Sernova has a 1 year low of C$0.12 and a 1 year high of C$0.23. The company has a 50 day simple moving average of C$0.15 and a two-hundred day simple moving average of C$0.16.

Sernova Company Profile

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.